Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Anoro Ellipta (umeclidinium bromide and vilanterol trifenatate) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
• This summary is based on the review of 12 systematic review(s)/meta-analysis(es). ^[1-12]
• UMEC/VI demonstrated significant improvements in FEV1, ranking second highest in overall efficacy (SUCRA 93.5%) and showing the highest efficacy in trough FEV1 improvement (Emax 0.185 L).
• UMEC/VI provided greater FEV1 improvement compared to monotherapies and placebo, with a 58% reduction in exacerbation risk.
• UMEC/VI consistently improved SGRQ scores and TDI focal scores across various studies, with improvements comparable to or greater than other LAMA/LABA combinations.
• UMEC/VI also reduced the need for rescue medication and demonstrated significant reductions in COPD exacerbations.
• UMEC/VI significantly reduced the annualized rate of moderate/severe exacerbations and showed a 58% reduction in exacerbation risk compared to placebo.
• The drug also exhibited a lower overall risk of exacerbations in a network meta-analysis compared to other LAMA/LABA combinations.
• No significant differences were observed in all-cause mortality and serious adverse cardiovascular events among LABA/LAMA FDCs.
• UMEC/VI demonstrated a similar safety profile to other LABA/LAMA combinations, showing no significant differences in major adverse cardiovascular events or pneumonia.
• UMEC/VI was well-tolerated and safe in general COPD populations and across different medication subgroups, including maintenance-naïve and ICS-free patients.
• There is no population type or subgroup information available in the reviewed studies.